Western blot results showed that hepatic levels of S100A9 were significantly increased in the NAFL and NASH groups compared with control (P < 0.05); however, S100A9 was slightly decreased in the NAFL + T2DM group compared with the NAFL group (P < 0.05). The gene discussed is S100A9; the disease is metabolic dysfunction-associated steatohepatitis.